Sign inJoin waitlistJoin the waitlist

Gary J. Schiller

Hematology & Oncology · The Regents of the University of California

Credentials: · · · ·

History

UCLA School of Medicine
Until 1990
UCLA School of Medicine
Until 1987
UCLA School of Medicine
Until 1985
Keck School of Medicine of the USC
1984

Research

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Blood · 2003 · 1,109 citations
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
The Lancet Oncology · 2015 · 1,047 citations
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid…
Journal of Clinical Oncology · 2018 · 802 citations

MT
Mary Territo
28 papers
Maria Baer
24 papers
Tara Lin
21 papers
Alice Mims
17 papers
William Blum
17 papers
Hillard Lazarus
16 papers
Martha Arellano
16 papers
Stephen Nimer
16 papers
Wendy Stock
16 papers
Eunice Wang
15 papers
ES
Eytan Stein
15 papers
JG
James Gajewski
15 papers

Clinical trials

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Principal investigator · Recruiting · Phase 1, Phase 2
AVM Biotechnology Inc
2020–2028
Stem Cell Gene Therapy for Sickle Cell Disease
Principal investigator · Completed · Phase 1, Phase 2
Donald B. Kohn, M.D.
2014–2025
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
Principal investigator · Completed · Phase 2
Chroma Therapeutics
2009–2011
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Principal investigator · Terminated · Phase 1
Jonsson Comprehensive Cancer Center
2007